Factor VIIa and its potential therapeutic use in bleeding-associated pathologies

Summary

Recombinant FVIIa (rFVIIa) was developed for treatment of haemophilia patients with inhibitors against FVIII/FIX. The haemostatic efficacy rate of 80–90% including major orthopaedic surgery (dosing of 90–120 µg/kg every other hour [h] for at least the first 24 h) was achieved in these patients. In a home-treatment setting the efficacy rate of haemostasis in mild-moderate bleedings was 92% (average number of 90 µg/kg doses was 2.2). A wide individual variation regarding recovery of rFVIIa (46 ± 12%; median 43%) as well as of clearance rate (36 ± 8 ml/kg/h; median 32 ml/kg/h in adults;children 2–3 times higher) has been observed. Thus children may require higher doses than adults. Accordingly the use of a dose of 270 µg/kg in one single injection was approved in the EU. Recent experience indicates that repeated doses of rFVIIa may decrease the number of bleeds in “target joints”, and thus may be useful as prophylaxis in severe hemophilia with inhibitors. Pharmacological concentrations of rFVIIa have been shown to enhance the thrombin generation on thrombin activated platelets in a cell-based model. By doing so a tight structured fibrin haemostatic plug resistant against premature lysis is formed. rFVIIa has been shown to induce haemostasis not only in haemophilia but also in other situations characterized by an impaired thrombin generation such as platelet defects, dilution coagulopathy developed as a result of trauma and extensive surgery. A special form of profuse bleeding, that may cause extensive problems is postpartum haemorrhage.

Keywords

Factor VIIa - haemophilia therapy - haemostasis - haemophilia A / B - tissue factor / factor VII

• References

• 1 Østerud B, Rapaport SI. Activation of factor IXby the reaction product of tissue factor and factor VII: Additional pathway for inititiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264.
• 2 Monroe DM. et al. Platelets and Thrombin Generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
• 3 Roberts HR. et al. Molecular biology and biochemistry of the coagulation factors and pathways of haemostasis. Williams Hematology. 6th Ed.. McGraw-Hill Companies Inc; 2001. Chapter 112: 1409-1434.
• 4 Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a “Prima Ballerina”. Thromb. Haemost 1995; 74: 7-17.
• 5 Hoffman M. et al. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007; 05: 1403-1408.
• 6 Shaw AW. et al. The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 2007; 282: 6556-6563.
• 7 Mandal S. et al. Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood 2005; 105: 153-160.
• 8 Chen VM. et al. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 1202-12028.
• 9 Manukyan D. et al. Protein disulfide isomerase as a trigger for tissue factor-dependent fibrin generation. Thromb Res 2008; 122 (Suppl. 01) S19-S22.
• 10 Reinhardt C. et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via activation of tissue factor. J Clin Invest 2008; 118: 1110-1122.
• 11 Cho J. et al. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 2008; 118: 1123-1131.
• 12 Pendurthi UR. et al. Tissue factor activation: is disulfide bond switching a regulatory mechanism?. Blood 2007; 110: 3900-3908.
• 13 Lopez-Vilchez I. et al. Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb Haemost 2007; 97: 202-211.
• 14 Panes O. et al. Human platelets synthesize and express functional tissue factor. Blood 2007; 109: 5242-5250.
• 15 Rauch U. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175.
• 16 Mandal SK. et al. Cellular localization and trafficking of tissue factor. Blood 2006; 107: 4746-4753.
• 17 Andrews RK. et al. Platelet adhesion receptors and (patho)physiological thrombus formation. Histol His-topathol 2001; 16: 969-980.
• 18 Pieters J. et al. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-1024.
• 19 Walsh PN. Platelet coagulation-protein interactions. Sem Thromb Haemostasis 2004; 30: 461-471.
• 20 Kjalke M. et al. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 05: 774-780.
• 21 Melton LG. et al. Location of the platelet binding site in zymogen coagulation factor IX. Blood Coag Fibrinol 2001; 12: 237-243.
• 22 Allen GA. et al. Impact of procoagulant concentration on rate, peak and total thrombin generation in a cell-based model system. J Thromb Haemost 2004; 02: 402-413.
• 23 Blombäck B. Fibrinogen and fibrin – proteins with complex roles in haemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
• 24 Collet JP. et al. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003; 278: 21331-21335.
• 25 Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-757.
• 26 Hedner U. et al. Studies on the thrombogenic activities in two prothrombin complex concentrates. Thromb Haemost 1979; 42: 1022-1032.
• 27 Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two haemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841.
• 28 Hedner U. et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 02: 1193.
• 29 Shapiro AD. et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
• 30 Lusher J. et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 09: 119-128.
• 31 Key NS. et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
• 32 Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a haemostatic agent. Clin Adv Hemat Onc 2003; 01: 112-119.
• 33 Monroe DM. et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-547.
• 34 Rao LVM, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of haemophilic bleeding by infused factor VIIa. Blood 1990; 75: 1069-1073.
• 35 Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 01: 307-317.
• 36 Telgt DSC. et al. Mechanism by which recombinant factor VIIa shortens the APTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56: 603-609.
• 37 Allen GA. et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of haemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-689.
• 38 Allen GA. et al. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006; 134: 314-319.
• 39 Lisman T. et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood 2002; 99: 175-179.
• 40 He S. et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 01: 1215-1219.
• 41 Lisman T. et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 03: 242-751.
• 42 Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of haemostasis. Ann Rev Med 2007; 59: 29-41.
• 43 Lindley CM. et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
• 44 Fridberg MJ. et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagulation Fibrinolysis 2005; 16: 259-266.
• 45 Hedner U. et al. Pharmacokinetics of rFVIIa in children. 23^rd Int Congress of the World Fed of Haemophilia. The Hague; The Netherlands: May 17-21 1998
• 46 Villar A. et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-359.
• 47 Kavakli K. et al. for the NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated FVII in patients with haemophilia and inhibitors. Thromb Haemost. 2006 95. 600-605.
• 48 Young G. et al. Single 270 ug/kg-dose rFVIIa vs. Standard 90 ug/kg-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-294.
• 49 Schulman S. et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-436.
• 50 Schulman S. The onerous task of comparing treatments in inhibitor patients. Thromb Haemost 2007; 98: 710-712.
• 51 Pruthi RK. et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Thromb Haemost 2007; 98: 726-732.
• 52 Hvas AM. et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A. J Thromb Haemost 2007; 05: 2408-2414.
• 53 Manco-Johnson MJ. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535-544.
• 54 Morfini M. et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-507.
• 55 Konkle BA. et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitor. J Thromb Haemost 2007; 05: 1904-1913.
• 56 Rapaport SI, Rao L V M. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-1121.
• 57 Mandal S. et al. Cellular localization and trafficking of tissue factor in fibroblasts. Blood 2006; 107: 4746-4753.
• 58 Kjalke M. et al. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haemotol 2001; 114: 114-120.
• 59 He S. et al. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005; 03: 272-279.
• 60 Galan AM. et al. Increased local procoagulant action: a mechanism contributing to the favourable haemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003; 43: 885-892.
• 61 Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transf Med Rev 2007; 21: 223-236.
• 62 Franchini M. et al. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coag Fibrinol 2006; 17: 615-619.
• 63 Karalapillai D, Popham P. Recombinant factor VIIa in massive postpartum haemorrhage. Int J Obs Anesth 2007; 16: 29-34.
• 64 Warren O. et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83: 707-714.
• 65 Warren OJ. et al. Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery?. Eur J Vasc Endovasc Surg 2008; 35: 145-152.
• 66 Friederich PW. et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103: 2555-2559.
• 67 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 02: 899-909.
• 68 Roberts HR. et al. Safety profile of recombinant factor VIIa. Sem Hematol 2004; 41 (Suppl. 01) 101-108.
• 69 O´Connell KA. et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. J Am Med Assoc 2006; 295: 293-298.
• 70 Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin He-matol 2007; 14: 225-229.
• 71 Laurian Y. et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSE-PA C study). Blood Coagul Fibrinolysis 1998; 09 (Suppl. 01) 155-156.
• 72 Santagostino E. et al. Home treatment woth recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999; 104: 22-26.
• 73 Hsia CC. et al. Use of recombinant activated factor VII in patients without haemophilia. A meta-analysis of randomized control trials. Ann Surg 2008; 248: 61-68.